# A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants

> **NCT06503679** · PHASE1 · COMPLETED · sponsor: **DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company** · enrollment: 49 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LY4100511 (DC-853) Dose 1
- **DRUG:** LY4100511 (DC-853) Dose 2
- **DRUG:** LY4100511 (DC-853) Dose 3
- **DRUG:** Midazolam
- **DRUG:** Repaglinide
- **DRUG:** Digoxin
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT06503679
- **Lead sponsor:** DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-16
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2025-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06503679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06503679, "A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06503679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*